title: ZD0473 treatment in lung cancer: an overview of the clinical trial results.
abstract: Three open-label, non-comparative, multicentre Phase II trials have examined the efficacy and tolerability of ZD0473 as first-and second-line therapy in non-small-cell lung cancer (NSCLC) patients and second-line therapy in small-cell lung cancer (SCLC) patients. Patients with second-line NSCLC or SCLC were evaluated as either platinum-sensitive or -resistant, based upon their time to relapse/progression after platinum-based therapy. First-line NSCLC patients (n = 18) received a total of 60 treatment cycles (median number per patient 2.5) whilst second-line NSCLC (n = 50) and SCLC (n = 48) patients both received a total of 127 treatment cycles (median number per patient 2.0). Grade 3/4 anaemia, neutropenia and thrombocytopenia was observed in: 38.8%, 22.2% and 27.7% of first-line NSCLC patients; 12.0%, 24.0% and 50% of second-line NSCLC patients; and 10.4%, 25.0% and 47.9% of second-line SCLC patients, respectively. The most common grade 3/4 non-haematological toxicities in all three trials were lethargy and dyspnoea. No clinically significant oto-, nephro- or neurotoxicity was observed. The first-line treatment of NSCLC produced an overall response rate (OR) of 6.3%. No OR was seen after second-line treatment of NSCLC, while ORs of 15.4% and 8.3% were seen in the platinum-resistant and -sensitive second-line SCLC patients, respectively.
authors.affiliation: Fox Chase Temple University Cancer Center, Philadelphia, PA, USA. treatja@tuhs.temple.edu
authors.forename: J
authors.initials: J
authors.lastname: Treat
authors.forename: J
authors.initials: J
authors.lastname: Schiller
authors.forename: E
authors.initials: E
authors.lastname: Quoix
authors.forename: A
authors.initials: A
authors.lastname: Mauer
authors.forename: M
authors.initials: M
authors.lastname: Edelman
authors.forename: M
authors.initials: M
authors.lastname: Modiano
authors.forename: P
authors.initials: P
authors.lastname: Bonomi
authors.forename: R
authors.initials: R
authors.lastname: Ramlau
authors.forename: E
authors.initials: E
authors.lastname: Lemarie
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D017322:Clinical Trials, Phase II as Topic; D018572:Disease-Free Survival; D019008:Drug Resistance, Neoplasm; D004417:Dyspnea / Q000139:chemically induced; D005260:Female; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009944:Organoplatinum Compounds / Q000627:therapeutic use*; D012894:Sleep Stages / Q000187:drug effects; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; C110525:amminedichloro(2-methylpyridine)platinum(II)